May 24, 2016 8:16 AM ET

Biotechnology

Company Overview of Palatin Technologies Inc.

Company Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of various diseases in the United States. The company’s clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that is in Phase 3 clinical trials for the treatment of female sexual dysfunction (FSD). Its drug development programs include Melanocortin receptor-1 agonist peptides for the treatment of inflammatory and dermatologic disease indications; Melanocortin receptor-4 peptide agonists, which is in preclinical trials for the treatment of erectile dysfunction; PL-3994, a natriuretic peptide receptor-A agonist that is in Phase 2 clinical trials for the tre...

4B Cedar Brook Drive

Cranbury, NJ 08512

United States

Founded in 1986

18 Employees

Phone:

609-495-2200

Fax:

609-495-2201

Key Executives for Palatin Technologies Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 53
Total Annual Compensation: $462.5K
Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer and Secretary
Age: 58
Total Annual Compensation: $422.5K
Compensation as of Fiscal Year 2015.

Palatin Technologies Inc. Key Developments

Palatin Technologies Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2016

Palatin Technologies Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2016. For the quarter, the company reported loss from operations of $12,085,748 against $8,722,391 a year ago. Loss before income taxes was $12,696,518 against $9,150,538 a year ago. Net loss was $12,696,518 or $0.08 per basic and diluted share against $9,150,538 or $0.07 per income diluted share a year ago. The difference between the three months ended March 31, 2016 and 2015 was primarily attributable to the increase in expenses relating to the Phase 3 clinical trial program with bremelanotide for FSD in the quarter ended March 31, 2016. For the nine months period, the company reported loss from operations of $36,511,823 against $5,505,865 a year ago. Loss before income taxes was $38,356,121 against $6,110,584 a year ago. Net loss was $38,356,121 or $0.25 per basic and diluted share against $5,579,076 or $0.05 per income diluted share a year ago.

Palatin Technologies Inc. to Report Q3, 2016 Results on May 17, 2016

Palatin Technologies Inc. announced that they will report Q3, 2016 results at 9:00 AM, Eastern Standard Time on May 17, 2016

Palatin Technologies Inc., Q3 2016 Earnings Call, May 17, 2016

Palatin Technologies Inc., Q3 2016 Earnings Call, May 17, 2016

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States
3D Biomatrix Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
July 2, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Palatin Technologies Inc., please visit www.palatin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.